Compare Novavax Inc (NVAX) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Synchrony Financial — how do they compare? Novavax Inc trades at $8.06 (market cap $1.30B), while Synchrony Financial trades at $71.7 (market cap $24.69B). The key difference: Synchrony Financial is far larger — about 19× Novavax Inc's market cap, and Synchrony Financial pays a 1.63% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | SYF | |
|---|---|---|
Market Cap | $1.30B | $24.69B |
Sector | Health | Financials |
52-Week High | $11.19 | $88.47 |
52-Week Low | $6.22 | $63.78 |
Enterprise Value | $800.50M | — |
Dividend Yield | — | 1.63% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
